Lacosamide Tablet was approved by NMPA

LACOSAMIDE TABLET WAS APPROVED BY NMPA

Our company, Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has obtained the approval of drug production registration for Lacosamide tablets (50mg and 100mg) from the National Medical Products Administration, which belongs to class 4 new chemical drugs and is regarded as passing the consistency evaluation.

Lacosamide can regulate the activity of sodium ion channel, effectively reduce sodium ion influx, reduce the excitability of neurons, and achieve the purpose of treating epilepsy, mainly used for the monotherapy and combination therapy of partial seizures in patients with epilepsy aged 4 years and above.